|RxNews Recap for Monday 01-11-10|
|By Mary Davila|
|Monday, 11 January 2010 19:06|
Below is a list of the companies that made news in the healthcare sector on Monday, January 11, 2010.
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.
AMAG Pharmaceuticals (NASDAQ:AMAG) expects 13 Million in sales for its drug Feraheme, topping Wall Street forecasts for the 4th quarter by a wide margin. Analyst had expected around $9.3 million for the drug which is intended to treat anemia in patients with chronic kidney disease.
A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that, on January 7, 2010, it received notice from the Nasdaq Stock Market (Nasdaq) confirming that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Listing Rule 5450(a)(1). Pursuant to Nasdaq's rules, the Company was required to achieve a closing bid price of at least $1.00 per share for 10 consecutive trading days which was completed on January 4, 2010.
Cel-Sci Corp (AMEX:CVM) completed the validation of its manufacturing facility and can begin manufacturing Multikine for phase 3 clinical trials with head and neck cancer patients. The facility will also be available to other manufacturers on a contract basis.
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has decided to suspend operations at its Preclinical Services (PCS) facility in Shrewsbury, Massachusetts, by the middle of 2010, when ongoing in-life studies will have been completed. Charles River intends to resume operations when global preclinical market conditions improve and the Company requires additional capacity.
EpiCept Corporation (NASDAQ: EPCT) Shares of Epicept Corp. soared over 30% today as the company announced an exclusive commercialization agreement for Ceplene with a leading international specialty pharmaceutical company Meda AB which is based in Stockholm. Celplene is EpiCepts novel therapy for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia.
Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that it has reached an agreement with a major Pharmacy chain to market the companies proprietary 7 Day Diet Aid Spray CRAVE-NX(TM) throughout the chains 7,000 stores. The product will arrive on the shelves beginning in January 2010.
Human Genome Sciences, Inc. (Nasdaq: HGSI) today will announce its priority goals for 2010 and report on the Company’s increasing momentum toward commercialization of late-stage products for systemic lupus and chronic hepatitis C in a presentation by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 28th Annual JPMorgan Healthcare Conference in San Francisco.
Imaging3(TM) Inc., (OTC BB:IMGG.OB) will host a conference call on Tuesday January 12th at 1PM PST to update investors with regards to the companies 510k FDA submission. The FDA is currently seeking additional information and IMGG CEO Mr. Dean Janes will discuss the companies plans to address these questions with shareholders.
MAP Pharma (NASDAQ:MAPP) said to today that a second efficacy trial will not be required by the FDA for Levadex, the companies experimental ,orally inhaled migraine drug. MAP announced that the phase III trial sufficiently met all four primary endpoints. Shares rose nearly 33% in Monday trading.
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reports that the Company has been invited to present on January 12th at the Biotech Showcase™, a conference designed to showcase promising companies and technologies for partnering and investment purposes.
VIVUS,Inc (NASDAQ:VVUS) shares headed north on Monday following news that its Phase III erectile-dysfunction drug candidate avanafil was effective within use of 15 minutes for the majority of the patients in the study.
Walgreens (NYSE, NASDAQ: WAG), which is offering H1N1 vaccinations at all of its pharmacies and Take Care Clinics nationwide, has administered more than one million H1N1 vaccinations to date this season – as widespread vaccine availability and greater access enable more people to get vaccinated.